Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock jumped 7.13% on Wednesday to $4.51 against a previous-day closing price of $4.21. With 0.45 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.6900 whereas the lowest price it dropped to was $4.1800. The 52-week range on MRNS shows that it touched its highest point at $13.15 and its lowest point at $3.97 during that stretch. It currently has a 1-year price target of $26.33. Beta for the stock currently stands at 1.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MRNS was down-trending over the past week, with a drop of -1.96%, but this was down by -7.01% over a month. Three-month performance dropped to -38.97% while six-month performance fell -7.96%. The stock lost -61.58% in the past year, while it has lost -62.04% so far this year. A look at the trailing 12-month EPS for MRNS yields -0.43 with Next year EPS estimates of -2.92. For the next quarter, that number is -0.62. This implies an EPS growth rate of 3.90% for this year and -758.80% for next year. EPS is expected to grow by 20.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 14.50%.
Float and Shares Shorts:
At present, 47.72 million MRNS shares are outstanding with a float of 47.50 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.38 million, which was 3.71% higher than short shares on Sep 14, 2022. In addition to Dr. Scott N. Braunstein M.D. as the firm’s CEO, Pres & Director, Mr. Steven E. Pfanstiel C.M.A., M.B.A. serves as its CFO & Treasurer.
Through their ownership of 79.00% of MRNS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 64.96% of MRNS, in contrast to 10.23% held by mutual funds. Shares owned by individuals account for 0.64%. As the largest shareholder in MRNS with 9.90% of the stake, Lion Point Capital LP holds 3,684,622 shares worth 3,684,622. A second-largest stockholder of MRNS, Suvretta Capital Management LLC, holds 3,537,700 shares, controlling over 9.51% of the firm’s shares. Point72 Asset Management LP is the third largest shareholder in MRNS, holding 3,390,000 shares or 9.11% stake. With a 3.13% stake in MRNS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,164,657 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.24% of MRNS stock, is the second-largest Mutual Fund holder. It holds 461,271 shares valued at 2.65 million. FTIF SICAV – Biotechnology Discov holds 0.78% of the stake in MRNS, owning 288,500 shares worth 1.66 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MRNS since 10 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MRNS analysts setting a high price target of $50.00 and a low target of $12.00, the average target price over the next 12 months is $25.11. Based on these targets, MRNS could surge 1008.65% to reach the target high and rise by 166.08% to reach the target low. Reaching the average price target will result in a growth of 456.76% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MRNS will report FY 2022 earnings on 03/13/2023. Analysts have provided yearly estimates in a range of $0.25 being high and -$0.71 being low. For MRNS, this leads to a yearly average estimate of -$0.36. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Marinus Pharmaceuticals Inc. surprised analysts by $1.46 when it reported $1.89 EPS against a consensus estimate of $0.43. The surprise factor in the prior quarter was -$0.62. Based on analyst estimates, the high estimate for the next quarter is -$0.08 and the low estimate is -$1.00. The average estimate for the next quarter is thus -$0.63.
Summary of Insider Activity:
Insiders traded MRNS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 151,728 while 0 shares were sold.